The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2020
DOI: 10.1038/s41598-020-69944-6
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of a SPM-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa by comparative genomics and phenotypic analysis

Abstract: Pseudomonas aeruginosa is one of the most common pathogens related to healthcare-associated infections. The Brazilian isolate, named CCBH4851, is a multidrug-resistant clone belonging to the sequence type 277. The antimicrobial resistance mechanisms of the CCBH4851 strain are associated with the presence of the bla SPM-1 gene, encoding a metallo-beta-lactamase, in combination with other exogenously acquired genes. Whole-genome sequencing studies focusing on emerging pathogens are essential to identify key feat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 58 publications
(86 reference statements)
0
3
0
Order By: Relevance
“…In addition, sequencing confirmed the presence of mutations in antimicrobial resistance-associated genes in some of the clinical isolates using P. aeruginosa PAO1 as a reference (Table 1). In general, some mutations in quinolone resistance determining regions (QRDRs) of GyrA, ParC, and ParE detected have been previously linked to fluoroquinolone resistance as well as the overexpression of efflux pump systems (Dunham et al, 2010;Subedi et al, 2018;Do Nascimento et al, 2020). In some isolates, the mexZ, nfxB, mexT, and mexR genes, which regulate the MexXY-OprM, MexCD-OprJ, MexEF-OprN, and MexAB-OprM multidrug efflux systems, revealed the presence of several point mutations predicted to result in several amino acid substitutions associated with resistance previously reported (Monti et al, 2013;López-Causapé et al, 2018b;Neves et al, 2019;Olsson et al, 2020).…”
Section: Diverse Genetic Background Of Multidrug-resistant Pseudomonas Aeruginosa Isolates Carrying Bla Kpc /Bla Vimmentioning
confidence: 99%
“…In addition, sequencing confirmed the presence of mutations in antimicrobial resistance-associated genes in some of the clinical isolates using P. aeruginosa PAO1 as a reference (Table 1). In general, some mutations in quinolone resistance determining regions (QRDRs) of GyrA, ParC, and ParE detected have been previously linked to fluoroquinolone resistance as well as the overexpression of efflux pump systems (Dunham et al, 2010;Subedi et al, 2018;Do Nascimento et al, 2020). In some isolates, the mexZ, nfxB, mexT, and mexR genes, which regulate the MexXY-OprM, MexCD-OprJ, MexEF-OprN, and MexAB-OprM multidrug efflux systems, revealed the presence of several point mutations predicted to result in several amino acid substitutions associated with resistance previously reported (Monti et al, 2013;López-Causapé et al, 2018b;Neves et al, 2019;Olsson et al, 2020).…”
Section: Diverse Genetic Background Of Multidrug-resistant Pseudomonas Aeruginosa Isolates Carrying Bla Kpc /Bla Vimmentioning
confidence: 99%
“…The structural differences between CCBH-2022 and PA01-2020 results from additional information available due to the new version of PAO1 and recent experimental work on characterising the complete closed genome of P. aeruginosa CCBH4851. 104 …”
Section: Discussionmentioning
confidence: 99%
“…Pseudomonas aeruginosa (P. aeruginosa ) is an aerobic, non-spore forming, Gram negative rods gamma proteobacterium [ 1 ]. The genome size of P. aeruginosa can reach 7.3 Mb, which contains core genes plus variable accessory genes [ 2 ]. P. aeruginosa is frequently associated with a wide range of acute and chronic infections, particularly infections of chronic wounds, such as pressure ulcers, diabetic ulcers, and venous ulcers, in addition to pneumonia in cystic fibrosis and cancer patients taking chemotherapy [ 3 , 4 ].…”
Section: Introductionmentioning
confidence: 99%